- Home
- Applications
- usa louisiana
- pre clinical effectiveness case study
Refine by
Pre Clinical Effectiveness Case Study Product Applications Available In Usa Louisiana
14 applications found
More than 500,000 U.S. patients have end stage renal disease, and over 80% of them utilize hemodialysis. A significant problem for dialysis patients is the development of a functioning and durable vascular access, preferably an arteriovenous fistula (AVF). After creation, about 60% of AVFs fail to mature successfully for dialysis use. This is due to inadequate vasodilation and smooth muscle cell hyperplasia at the distal venous ...
ByEndomimetics based in Birmingham, ALASKA (USA)
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. The use of directed liposomes has allowed the advance of many cancer drugs to preclinical and clinical trials, reducing side effects, and increasing their therapeutic index at the same time. More than 15 cancer liposomed drugs are currently clinically ...
ByNanovex Biotechnologies based in Llanera, SPAIN
MIRRAGEN Advanced Wound Matrix was tested in a clinically relevant porcine wound model under GLP ...
ByETS Wound Care based in Rolla, MISSOURI (USA)
More than 3% of the population has unruptured cerebral aneurysms, approximately 10 million people in the US. About 30,000 rupture per year, with devastating consequences. More than 30% of patients with ruptured aneurysms die, and 4 of 7 who survive have significant disabilities. Detachable microcoils are now used in more than 70% of treated aneurysms. The risk of recurrence, or recanalization, remains surprisingly high at approximately 20-30%. Various modifications are used clinically with limited evidence that ...
ByEndomimetics based in Birmingham, ALASKA (USA)
Like other nanocarriers, synthetic exosomes can be used to treat different types of cancer successfully, by encapsulating the desired anti-tumoral drug or RNA and enzymes. Several studies have used engineered exosomes from dendritic or macrophage cells to release chemotherapeutic compounds as doxorubicin, paclitaxel miRNA or siRNA to induce antitumoral activity. Rodent mammary carcinoma, mice lung cancer, glioma and pancreatic cancer are just some targeted diseases in preclinical testing using exosome delivery ...
ByNanovex Biotechnologies based in Llanera, SPAIN
For many years, researchers have investigated cell and gene therapies as potential replacement therapies for severe chronic diseases. Despite major advancements in the field, these approaches carry a number of limitations including immune rejection, limited eligibility, durability and variability challenges, inability to re-dose and high manufacturing costs. To address these drawbacks, we developed our novel Shielded Living Therapeutics™ (SLTx) platform, which we believe has the potential to result in ...
ByEli Lilly and Company based in Indianapolis, INDIANA (USA)
Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. Preclinical studies suggest that, once implanted, the scaffold seeded with the patient’s own cells signals the stem cell niche to guide the regeneration of a biological ...
ByHarvard Apparatus Regenerative Technology, Inc. formely known as Biostage, Inc. based in Holliston, MASSACHUSETTS (USA)
Thermal Management: Pyroid HT pyrolytic graphite thermal spreaders and thermal vias are a powerful new material solution in the battle against thermal heat in state-of-the-art electronic circuits and devices. HT material matches the heat spreading capability of CVD diamond at 1700 W/mK but at substantially better economics. ...
ByCETCO based in New York, NEW YORK (USA)
The IntraOp® Mobetron® is the most comprehensive electron therapy linear accelerator system with applications in intraoperative radiotherapy (IORT) and non-invasive treatment of skin cancer. Now Mobetron is the first to offer ultra-high dose rate electron therapy for preclinical and investigational studies of FLASH radiotherapy on an established clinical radiotherapy platform. IntraOp’s advanced technology ushers in a new paradigm for cancer treatment by providing researchers an approach not possible ...
ByIntraOp Medical, Inc. based in Sunnyvale, CALIFORNIA (USA)
Glooko real-world patient data for retrospective studies and a global network of 7,500+ clinics for randomized clinical ...
ByGlooko, Inc. based in Palo Alto, CALIFORNIA (USA)
Ventricular Tachycardia (VT) is a complex condition that has many underlying causes, varying degrees of symptoms, and potentially fatal outcomes if not treated effectively. ...
ByThermedical, Inc. based in Waltham, MASSACHUSETTS (USA)
Stents are the most common cardiovascular implants used in the treatment of cardiovascular diseases. However, there are concerns about in-stent renarrowing (restenosis) with bare metal stents and late stent thrombosis and inflammatory responses with drug-eluting stents. The endothelium is the lining of the blood vessels that is a thin layer of endothelial cells and underlying nanofibrillar basement membrane. It modulates vascular tone by release of factors such as nitric oxide. With stent deployment, there is ...
ByEndomimetics based in Birmingham, ALASKA (USA)
When you’re developing the next generation of small molecule therapeutics, biologics, or vaccines, getting reliable data is critical for success. So is speed. With products and services that can boost productivity, support regulatory compliance, and shorten time-to-market while ensuring high-quality assay results, Artel is helping BioPharma teams get ahead and stay ...
ByArtel, Inc. by Advanced Instruments based in Westbrook, MAINE (USA)
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)